Advertisement
UK markets close in 6 hours 19 minutes

  • FTSE 100

    8,105.54
    +26.68 (+0.33%)
     

  • FTSE 250

    19,809.64
    +207.66 (+1.06%)
     

  • AIM

    755.85
    +2.73 (+0.36%)
     

  • GBP/EUR

    1.1657
    +0.0000 (+0.00%)
     

  • GBP/USD

    1.2520
    +0.0009 (+0.07%)
     

  • Bitcoin GBP

    51,483.71
    +230.94 (+0.45%)
     

  • CMC Crypto 200

    1,388.95
    -7.59 (-0.54%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.70
    +0.13 (+0.16%)
     

  • GOLD FUTURES

    2,359.10
    +16.60 (+0.71%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,048.03
    +130.75 (+0.73%)
     

  • CAC 40

    8,038.20
    +21.55 (+0.27%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

BUZZ-GlaxoSmithKline gains on first Citi 'buy' in three years

Reuters - UK Focus

** GlaxoSmithKline (Other OTC: GLAXF - news) up 1.4% as Citigroup (NYSE: C - news) puts "buy" rating on stock for first time in more than three years; previous rating "neutral"

** Citi analysts say company's drug pipeline is modest but credible and undervalued, especially within oncology, with near term focus on epigenetics and longer term immuno-oncology

** Planned appointment of a new CEO in 2017 increases the possibility of a value-enhancing divestment of the consumer business and increased cost reduction

(RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)